These cells are characterized as basal-like/triple-negative breast cancer cells; lacking expression of estrogen receptor-α (ER), progesterone receptor (PR) and ErbB2/neu (HER2), which represent a highly aggressive breast cancer subtype, that is resistant to treatment and is associated with poor prognosis (41). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.